ByteDance's AI drug unit presents therapies at global conferences
Anew Therapeutics, also known as ByteDance AI Drug Discovery, is showcasing AI-generated therapies at global conferences. The division has teams based in Boston, Rio de Janeiro, and Barcelona, with operational hubs in Shanghai, Singapore, and San Jose, California. Their website features 36 core team members and a scientific advisory board that includes Liu Yongjun (former president of Innovent Biologics), Ji Ma (ex-principal scientist at Amgen), and Hua Zou (scientific director of protein chemistry at Takeda California). In mid-April, Chris Li, the biology lead, presented one of Anew Labs' four drug candidates at Immunology2026 in Boston, while She Yuli, head of data, participated in the International Conference on Learning Representations in late April. Yu Haoyu, head of computational chemistry, announced his attendance at the 2026 Free Energy Workshop in Barcelona starting May 4, where he will introduce AnewSampling, a framework for all-atom molecular dynamics.
Key facts
- ByteDance's drug unit is named Anew Therapeutics or ByteDance AI Drug Discovery.
- The unit operates from Shanghai, Singapore, and San Jose, California.
- It fields teams in Boston, Rio de Janeiro, and Barcelona.
- The scientific advisory board includes Liu Yongjun, Ji Ma, and Hua Zou.
- Chris Li presented an AI-designed drug candidate for autoimmune diseases at Immunology2026 in Boston.
- She Yuli attended the International Conference on Learning Representations in Rio de Janeiro.
- Yu Haoyu will present AnewSampling at the 2026 Free Energy Workshop in Barcelona.
- The unit lists 36 core members on its website.
Entities
Institutions
- ByteDance
- Anew Therapeutics
- ByteDance AI Drug Discovery
- Anew Labs
- Innovent Biologics
- Amgen
- Takeda California
- American Association of Immunologists
- International Conference on Learning Representations
Locations
- Boston
- Rio de Janeiro
- Barcelona
- Shanghai
- Singapore
- San Jose
- California
- Spain